Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

1-25 of 60 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3

Physical Activity Decreases Inflammation and Delays the Development of Obesity-Associated Pancreatic Ductal Adenocarcinoma.
Pita-Grisanti V, Velez-Bonet E, Chasser K, Hurst Z, Liette A, Vulic G, Dubay K, Lahooti A, Badi N, Ueltschi O, Gumpper-Fedus K, Hsueh HY, Lahooti I, Chavez-Tomar M, Terhorst S, Knoblaugh SE, Cao L, Huang W, Coss CC, [...] Cruz-Monserrate Z
Cancer Res, 84(18):3058-3071, 01 Sep 2024
Cited by: 1 article | PMID: 38781455
Add to export list
Merging Natural Product Structures with Pharmaceutical Leads: Unnatural Enantiomers of Estranes as Glucocorticoid Receptor Modulators That Suppress TNF-α and IL-6 Release.
Nicholson JM, Yang D, Koelblen T, Hu EL, Coss CC, Burris TP, Hu X, Micalizio GC
J Med Chem, 67(18):16185-16194, 06 Sep 2024
Cited by: 0 articles | PMID: 39240657
Add to export list
The elucidation of species-specific receptor pharmacology: a case study using subtype selective para- and meta-carborane estrogen receptor agonists.
Adeluola AA, Radomska HS, Wilson TA, Kulp SK, Kabat A, Helms TH, Mayo AK, Montgomery EJ, Thomas J, Marcho LM, Costa T, Fukuda M, Kang DD, Vibhute S, Wang D, Bennett CE, Coss CC
J Pharmacol Exp Ther, JPET-AR-2023-001874, 27 Jun 2024
Cited by: 0 articles | PMID: 38936980
Add to export list
Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models.
Rodriguez-Blanco J, Salvador AD, Suter RK, Swiderska-Syn M, Palomo-Caturla I, Kliebe V, Shahani P, Peterson K, Turos-Cabal M, Vieira ME, Wynn DT, Howell AJ, Yang F, Ban Y, McCrea HJ, Zindy F, Danis E, Vibhakar R, Jermakowicz A, [...] Robbins DJ
J Clin Invest, 134(15):e171136, 17 Jun 2024
Cited by: 0 articles | PMID: 38885332 | PMCID: PMC11290968
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia.
Elgamal OA, Fobare S, Vibhute S, Mehmood A, Vroom DC, Johnson ML, Stearns B, Lerma JR, Truxall J, Stahl E, Carmichael B, Orwick SJ, Mims AS, Curran E, Santhanam R, Tridandapani S, Phelps MA, Xie Z, Coss CC, [...] Byrd JC
JCI Insight, 9(8):e173646, 22 Apr 2024
Cited by: 0 articles | PMID: 38646934 | PMCID: PMC11141866
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Function-Oriented Synthesis of Pentacyclic Triterpenoids and Discovery of an <i>ent</i>-Estrane as a Natural Product-Inspired Androgen Receptor Antagonist.
Stempel ZD, Radomska HS, Coss CC, Micalizio GC
Org Lett, 26(15):3054-3059, 01 Apr 2024
Cited by: 0 articles | PMID: 38557107
Add to export list
Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31.
Silvaroli JA, Bisunke B, Kim JY, Stayton A, Jayne LA, Martinez SA, Nguyen C, Patel PS, Vanichapol T, Verma V, Akhter J, Bolisetty S, Madhavan SM, Kuscu C, Coss CC, Zepeda-Orozco D, Parikh SV, Satoskar AA, Davidson AJ, [...] Bajwa A
J Am Soc Nephrol, 35(6):681-695, 26 Mar 2024
Cited by: 1 article | PMID: 38530359
Add to export list
Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors.
Guo Y, Remaily BC, Thomas J, Kim K, Kulp SK, Mace TA, Ganesan LP, Owen DH, Coss CC, Phelps MA
Clin Cancer Res, 30(5):942-958, 01 Mar 2024
Cited by: 0 articles | PMID: 37921739 | PMCID: PMC10922515
Add to export list Review Free full text in Europe PMC
Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia.
Vu TT, Kim K, Manna M, Thomas J, Remaily BC, Montgomery EJ, Costa T, Granchie L, Xie Z, Guo Y, Chen M, Castillo AMM, Kulp SK, Mo X, Nimmagadda S, Gregorevic P, Owen DH, Ganesan LP, Mace TA, [...] Phelps MA
Pharmacol Res, 199:107048, 23 Dec 2023
Cited by: 1 article | PMID: 38145833 | PMCID: PMC10798214
Add to export list Free full text in Europe PMC
Potent Estrogen Receptor β Agonists with Inhibitory ActivityIn Vitro, Fail to Suppress Xenografts of Endocrine-Resistant Cyclin-dependent Kinase 4/6 inhibitor-Resistant Breast Cancer Cells
Marcho LM, Coss CC, Xu M, Datta J, Manouchehri JM, Cherian MA
bioRxiv, 15 Jan 2024
Cited by: 0 articles | PPR: PPR787166
Add to export list Preprint
The MYC axis in advanced prostate cancer is impacted through concurrent targeting of ERβ and AR using a novel ERβ-selective ligand alongside Enzalutamide
Gray JS, Wani SA, Hussain S, Huang P, Nayak D, Long MD, Yates C, Clinton SK, Bennet CE, Coss CC, Campbell MJ
bioRxiv, 17 Nov 2023
Cited by: 0 articles | PPR: PPR760802
Add to export list Preprint
Exploration of Verticillins in High-Grade Serous Ovarian Cancer and Evaluation of Multiple Formulations in Preclinical In Vitro and In Vivo Models.
Kaweesa EN, Bazioli JM, Pierre HC, Lantvit DD, Kulp SK, Hill KL, Phelps MA, Coss CC, Fuchs JR, Pearce CJ, Oberlies NH, Burdette JE
Mol Pharm, 20(6):3049-3059, 08 May 2023
Cited by: 1 article | PMID: 37155928 | PMCID: PMC10405366
Add to export list Free full text in Europe PMC
Physical Activity Delays Obesity-Associated Pancreatic Ductal Adenocarcinoma in Mice and Decreases Inflammation
Pita-Grisanti V, Dubay K, Lahooti A, Badi N, Ueltschi O, Gumpper-Fedus K, Hsueh H, Lahooti I, Chavez-Tomar M, Terhorst S, Knoblaugh SE, Cao L, Huang W, Coss CC, Mace TA, Choueiry F, Hinton A, Mitchell JM, Schmandt R, [...] Cruz-Monserrate Z
bioRxiv, 04 Jan 2023
Cited by: 0 articles | PPR: PPR591219
Add to export list Preprint
Constitutively Active Androgen Receptor in Hepatocellular Carcinoma.
Montgomery EJ, Xing E, Campbell MJ, Li PK, Blachly JS, Tsung A, Coss CC
Int J Mol Sci, 23(22):13768, 09 Nov 2022
Cited by: 4 articles | PMID: 36430245 | PMCID: PMC9699340
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer.
Thomas J, Torok MA, Agrawal K, Pfau T, Vu TT, Lyberger J, Chang H, Castillo AMM, Chen M, Remaily B, Kim K, Xie Z, Dillhoff ME, Kulp SK, Behbehani GK, Cruz-Monserrate Z, Ganesan LP, Owen DH, Phelps MA, [...] Mace TA
Int J Mol Sci, 23(13):7066, 25 Jun 2022
Cited by: 4 articles | PMID: 35806069 | PMCID: PMC9266939
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer
Datta J, Willingham N, Manouchehri JM, Schnell P, Sheth M, David JJ, Kassem M, Wilson TA, Radomska HS, Coss CC, Bennett CE, Ganju RK, Sardesai SD, Lustberg M, Ramaswamy B, Stover DG, Cherian MA
bioRxiv, 17 Jan 2022
Cited by: 0 articles | PPR: PPR443350
Add to export list Preprint
Discovery of Anticancer Agents of Diverse Natural Origin.
Aldrich LN, Burdette JE, Carcache de Blanco E, Coss CC, Eustaquio AS, Fuchs JR, Kinghorn AD, MacFarlane A, Mize BK, Oberlies NH, Orjala J, Pearce CJ, Phelps MA, Rakotondraibe LH, Ren Y, Soejarto DD, Stockwell BR, Yalowich JC, Zhang X
J Nat Prod, 85(3):702-719, 25 Feb 2022
Cited by: 18 articles | PMID: 35213158 | PMCID: PMC9034850
Add to export list Free full text in Europe PMC
Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer.
Datta J, Willingham N, Manouchehri JM, Schnell P, Sheth M, David JJ, Kassem M, Wilson TA, Radomska HS, Coss CC, Bennett CE, Ganju RK, Sardesai SD, Lustberg M, Ramaswamy B, Stover DG, Cherian MA
Front Oncol, 12:857590, 25 Apr 2022
Cited by: 10 articles | PMID: 35574319 | PMCID: PMC9097292
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.
Guo Y, Wei L, Patel SH, Lopez G, Grogan M, Li M, Haddad T, Johns A, Ganesan LP, Yang Y, Spakowicz DJ, Shields PG, He K, Bertino EM, Otterson GA, Carbone DP, Presley C, Kulp SK, Mace TA, [...] Owen DH
Clin Lung Cancer, 23(4):345-355, 08 Jan 2022
Cited by: 16 articles | PMID: 35131184 | PMCID: PMC9149057
Add to export list Free full text in Europe PMC
Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing.
Liva S, Chen M, Mortazavi A, Walker A, Wang J, Dittmar K, Hofmeister C, Coss CC, Phelps MA
Eur J Drug Metab Pharmacokinet, 46(6):807-816, 07 Oct 2021
Cited by: 1 article | PMID: 34618345 | PMCID: PMC8599380
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Derivation of anthropometric-based equations to predict lean body mass composition of cancer patients
Carey AB, Felix AS, Huling JD, Odei JB, Coss CC, Ning X, Donneyong MM
medRxiv, 07 Jul 2021
Cited by: 0 articles | PPR: PPR366949
Add to export list Preprint
Structure-Activity Relationship of para-Carborane Selective Estrogen Receptor β Agonists.
Sedlák D, Wilson TA, Tjarks W, Radomska HS, Wang H, Kolla JN, Leśnikowski ZJ, Špičáková A, Ali T, Ishita K, Rakotondraibe LH, Vibhute S, Wang D, Anzenbacher P, Bennett C, Bartunek P, Coss CC
J Med Chem, 64(13):9330-9353, 28 Jun 2021
Cited by: 9 articles | PMID: 34181409
Add to export list
Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks.
Helms TH, Mullins RD, Thomas-Ahner JM, Kulp SK, Campbell MJ, Lucas F, Schmidt N, LeMoine DM, Getaneh S, Xie Z, Phelps MA, Clinton SK, Coss CC
Sci Rep, 11(1):3646, 11 Feb 2021
Cited by: 5 articles | PMID: 33574348 | PMCID: PMC7878907
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.
Zhang P, Brinton LT, Williams K, Sher S, Orwick S, Tzung-Huei L, Mims AS, Coss CC, Kulp SK, Youssef Y, Chan WK, Mitchell S, Mustonen A, Cannon M, Phillips H, Lehman AM, Kauffman T, Beaver L, Canfield D, [...] Lapalombella R
Clin Cancer Res, 27(8):2352-2366, 04 Feb 2021
Cited by: 16 articles | PMID: 33542077 | PMCID: PMC8054771
Add to export list Free full text in Europe PMC
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Collier KA, Valencia H, Newton H, Hade EM, Sborov DW, Cavaliere R, Poi M, Phelps MA, Liva SG, Coss CC, Wang J, Khountham S, Monk P, Shapiro CL, Piekarz R, Hofmeister CC, Welling DB, Mortazavi A
Cancer Chemother Pharmacol, 87(5):599-611, 25 Jan 2021
Cited by: 12 articles | PMID: 33492438 | PMCID: PMC8162746
Add to export list Free full text in Europe PMC

1-25 of 60 results

1 2 3

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

Physical Activity Decreases Inflammation and Delays the Development of Obesity-Associated Pancreatic Ductal Adenocarcinoma.

Merging Natural Product Structures with Pharmaceutical Leads: Unnatural Enantiomers of Estranes as Glucocorticoid Receptor Modulators That Suppress TNF-α and IL-6 Release.

**The elucidation of species-specific receptor pharmacology: a case study using subtype selective para- and meta-carborane estrogen receptor agonists**.

Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models.

Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia.

Function-Oriented Synthesis of Pentacyclic Triterpenoids and Discovery of an <i>ent</i>-Estrane as a Natural Product-Inspired Androgen Receptor Antagonist.

Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31.

Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors.

Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia.

Potent Estrogen Receptor β Agonists with Inhibitory ActivityIn Vitro, Fail to Suppress Xenografts of Endocrine-Resistant Cyclin-dependent Kinase 4/6 inhibitor-Resistant Breast Cancer Cells

The MYC axis in advanced prostate cancer is impacted through concurrent targeting of ERβ and AR using a novel ERβ-selective ligand alongside Enzalutamide

Exploration of Verticillins in High-Grade Serous Ovarian Cancer and Evaluation of Multiple Formulations in Preclinical In Vitro and In Vivo Models.

Physical Activity Delays Obesity-Associated Pancreatic Ductal Adenocarcinoma in Mice and Decreases Inflammation

Constitutively Active Androgen Receptor in Hepatocellular Carcinoma.

The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer.

Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer

Discovery of Anticancer Agents of Diverse Natural Origin.

Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer.

Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.

Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing.

Derivation of anthropometric-based equations to predict lean body mass composition of cancer patients

Structure-Activity Relationship of para-Carborane Selective Estrogen Receptor β Agonists.

Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks.

Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.

Partnerships & funding